arrow
M

Matthew Adamow

memorial sloan kettering cancer center
H指数:14
被引数:5,367
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

在去分化脂肪肉瘤中序贯使用CDK4/6和PD-1抑制剂后的肿瘤与免疫动态变化:一项2期研究的结果

2026-02-010
PRE
Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

外周血(PB)T细胞表型和肿瘤微环境(TME)亚型与肉瘤中免疫检查点阻断(ICB)的疗效独立相关

2024-09-010
PRE
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
2024-08-270
OAAI
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab plus Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
2024-05-201
PRE
Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
2024-04-050
PRE
A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy
2023-08-010
OAAI
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
2021-08-2565
OA
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

肠道菌群特征与联合CTLA-4和PD-1阻断的毒性有关

2021-07-08251
OAAI
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child
2021-06-2887
OAAI
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
2020-11-0241
OAAI
Mucosal-associated invariant and γδ T cell subsets respond to initial Mycobacterium tuberculosis infection
2018-10-0453
OA
Mammalian GW220/TNGW1 is essential for the formation of GW/P bodies containing miRISC
2012-08-1316
OAAI
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

黑色素瘤患者的远位效应的免疫学相关性

2012-03-081.8K
OAAI
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

整合的NY-ESO-1抗体和CD8 T细胞反应与ipilimumab治疗的晚期黑色素瘤患者的临床益处相关

2011-09-20293
OAAI
Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection
2010-07-2842
OAAI